6. GlaxoSmithKline Benlysta (belimumab, the first new lupus treatment in 60 years) approved by FDA in March. Six products in total approved
by US and EU; seven more filed with regulators. Malaria vaccine in Phase III trials in Africa, with 30 other late-stage assets.
Julian Heslop retired as CFO, succeeded by Simon Dingemans. Patents for active ingredients in Seretide/Advair expired.
7. AstraZeneca Crestor substance patent upheld in US court. Approvals include Vimovo (naproxen/esomeprazole magnesium) in US and EU and
Brilique (atherothrombotic event prevention) in EU. Kombiglyze XR, the only once-daily dose of DPP4/metformin, developed with
Bristol-Myers Squibb, also approved in US. Nine molecules in Phase III trials or submitted for regulatory approval, with another
92 projects in development. Completed deal with Rigel for development of fostamatinib (rheumatoid arthritis).
8. Johnson & Johnson Completed tender offer for Crucell N.V. in February 2011; acquired 98.93 percent of shares. Products under regulatory review
include: Rivaroxoban for stroke prevention in patients with atrial fibrillation (US), Telaprevir for hepatitis C (US and EU),
Abiraterone acetate for metastatic advanced prostate (US and EU), and rilpivirine for HIV. Eight more candidates planned for
regulatory submission from 2011 to 2013.
9. Eli Lilly Completed acquisition of Alnara and Avid Radiopharmaceuticals. Launched statin Livalo in the US with partner Kowa. Has 68
molecules in development. Several monoclonal antibodies for cancer in late-stage development. Phase III candidates include
Necitumumab for non-small-cell lung cancer and Ramucirumab for metastatic breast and gastric cancers. Signed commercialization
deal with Acrux for newly approved experimental testosterone solution Axiron.
10. Abbott The year was marked by acquisitions, including the pharmaceutical business of Solvay for $6.1 billion plus milestones, and
Piramal Healthcare's Healthcare Solutions business, a leader in the Indian branded generics market, for $2.2 billion in cash,
plus $1.6 billion in annual payments through 2014. Additional acquisitions included Advanced Medical Optics, STARLIMS Technologies
(informatics), and the remaining shares of Facet Biotech.
About the Authors
Jerry Cacciotti is a Partner in Oliver Wyman's Health and Life Sciences Practice. He can be reached at Jerry.Cacciotti@oliverwyman.com
Patrick Clinton is Marketing Director in the Health & Life Sciences practice of Oliver Wyman. He can be reached at Patrick.Clinton@oliverwyman.com
|
PharmExec Blog
Follow Us
RSS
Bookstore
